Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline | Zendy

David Blacker | Zendy; David Prentice | Zendy; Anthony Alvaro | Zendy; Timothy R. Bates | Zendy; Michael Bynevelt | Zendy; Andrew P. Kelly | Zendy; Lay Kun Kho | Zendy; E. Kohler | Zendy; Graeme J. Hankey | Zendy; A. N. Thompson | Zendy; Taryn Major | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reducing Haemorrhagic Transformation after Thrombolysis for Stroke: A Strategy Utilising Minocycline

Author(s) -

David Blacker,

David Prentice,

Anthony Alvaro,

Timothy R. Bates,

Michael Bynevelt,

Andrew P. Kelly,

Lay Kun Kho,

E. Kohler,

Graeme J. Hankey,

A. N. Thompson,

Taryn Major

Publication year - 2013

Publication title -

stroke research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.939

H-Index - 34

eISSN - 2090-8105

pISSN - 2042-0056

DOI - 10.1155/2013/362961

Subject(s) - minocycline , medicine , thrombolysis , stroke (engine) , ischaemic stroke , tissue plasminogen activator , clinical endpoint , clinical trial , complication , brain ischemia , anesthesia , ischemia , antibiotics , myocardial infarction , mechanical engineering , microbiology and biotechnology , biology , engineering

Haemorrhagic transformation (HT) of recently ischaemic brain is a feared complication of thrombolytic therapy that may be caused or compounded by ischaemia-induced activation of matrix metalloproteinases (MMPs). The tetracycline antibiotic minocycline inhibits matrix MMPs and reduces macroscopic HT in rodents with stroke treated with tissue plasminogen activator (tPA). The West Australian Intravenous Minocycline and TPA Stroke Study (WAIMATSS) aims to determine the safety and efficacy of adding minocycline to tPA in acute ischaemic stroke. The WAIMATSS is a multicentre, prospective, and randomised pilot study of intravenous minocycline, 200 mg 12 hourly for 5 doses, compared with standard care, in patients with ischaemic stroke treated with intravenous tPA. The primary endpoint is HT diagnosed by brain CT and MRI. Secondary endpoints include clinical outcome measures. Some illustrative cases from the early recruitment phase of this study will be presented, and future perspectives will be discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research